Bayer has sold a minority, non-controlling stake in its newly established long-acting reversible contraceptives business to Apollo for €3 billion. The deal, expected to close in the third quarter of 2026, gives Apollo a stake in products including Mirena, Jaydess, Kyleena, and Jadelle while Bayer retains full operational control. CFO Dr Judith Hartmann said the transaction strengthens Bayer's capital structure and enhances financial flexibility amid bond maturities and litigation costs, including those related to the Roundup weed killer. The move comes as Bayer pursues a broader pharma dealmaking strategy, recently announcing a $2.45 billion acquisition of Perfuse Therapeutics to build on its Eylea franchise.
Bayer AG NABayer sells minority stake for €3bn, strengthening capital structure and financial flexibility.
Apollo Global Management LLC Class AApollo invests €3bn in Bayer's contraceptives business, gaining a minority stake.